Gancotamab

DB14784Investigational

Gancotamab is under investigation in clinical trial NCT02213744 (MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients).

Mechanism: Pharmacologically active on Receptor tyrosine-protein kinase erbB-2 and DNA topoisomerase 2-alpha
Curator reviewed
Code names: MM-302

Resolves to

Compound

UNIIS5Z216QNO6CAS1509928-00-0

Targets

P04626ERBB2P11388TOP2A

What you can answer from here — as of June 15, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

382Drug interactionsStructured to mechanism, not free text

3Clinical trialsPhase, status and sponsor resolved per trial

5+ReferencesStructured and connected to the statements they support

Which drugs share a target with Gancotamab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account